GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » ROC (Joel Greenblatt) %

TME Pharma NV (XPAR:ALTME) ROC (Joel Greenblatt) % : -8,393.85% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. TME Pharma NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -8,393.85%.

The historical rank and industry rank for TME Pharma NV's ROC (Joel Greenblatt) % or its related term are showing as below:

XPAR:ALTME' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13997.84   Med: -3695.62   Max: -962.92
Current: -5573.63

During the past 10 years, TME Pharma NV's highest ROC (Joel Greenblatt) % was -962.92%. The lowest was -13997.84%. And the median was -3695.62%.

XPAR:ALTME's ROC (Joel Greenblatt) % is ranked worse than
86.38% of 1410 companies
in the Biotechnology industry
Industry Median: -307.055 vs XPAR:ALTME: -5573.63

TME Pharma NV's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -6.60% per year.


TME Pharma NV ROC (Joel Greenblatt) % Historical Data

The historical data trend for TME Pharma NV's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV ROC (Joel Greenblatt) % Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -962.92 -4,100.38 -13,997.84 -8,171.43 -3,290.85

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27,301.82 -6,366.79 -2,630.81 -4,181.40 -8,393.85

Competitive Comparison of TME Pharma NV's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, TME Pharma NV's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's ROC (Joel Greenblatt) % falls into.



TME Pharma NV ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.141) - (1.167 + 0 + 0.452)
=-1.478

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.196) - (1.039 + 0 + 0.331)
=-1.174

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of TME Pharma NV for the quarter that ended in Jun. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.456/( ( (0.096 + max(-1.478, 0)) + (0.034 + max(-1.174, 0)) )/ 2 )
=-5.456/( ( 0.096 + 0.034 )/ 2 )
=-5.456/0.065
=-8,393.85 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TME Pharma NV  (XPAR:ALTME) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


TME Pharma NV ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV Headlines

No Headlines